Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, has announced the following changes to its Board of Directors.
Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin “Allen” Han, and Dr Yuelong Huang (all Non-Executive Directors of the Company), will step down from the Board and not seek re-election at the Company’s upcoming Annual General Meeting which is expected to be held in July 2020. Once these Board changes become effective in July 2020, the Board will decrease from 12 members to eight members and will comprise of three executive directors and five non-executive directors.
The audited results for the year ended 31 December 2019 are expected to be announced on or around 29 June 2020. The annual report and accounts will be published shortly thereafter and posted to shareholders together with the notice of AGM.
Dr Mike Sinclair, executive chairman of Advanced Oncotherapy, commented: “On behalf of the Board, I would like to thank Gabriel, Peter, Allen and Yuelong for their strategic counsel and insight to Advanced Oncotherapy over the years. As valued Board members, they have helped Advanced Oncotherapy to progress to a leading position as a technology disruptor in proton therapy, and we wish them all the best in their future endeavours.”